Status and phase
Conditions
Treatments
About
The objective of this study is to evaluate the effectiveness of SCTV01E in participants aged ≥18 years.
Full description
The study is a randomized, double-blind, placebo-controlled Phase III study. It will evaluate the protective effectiveness and safety of SCTV01E against COVID-19 in participants who were previously received primary series or booster dose of COVID-19 vaccines.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10,000 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Yu Sun
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal